Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
Acrivon selected ACR-7280, a potential first-in-class oral CDK11 inhibitor, as its next development candidate and is running IND-enabling studies with FDA IND submission targeted for the first half of 2027. In preclinical work, ACR-7280 produced complete tumor regression in aggressive AML xenograft models and showed strong synergy with venetoclax and menin inhibitors; initial development will focus on AML.
Key figures
- Drug Name
- ACR-7280
- Phase Of Trial
- IND-enabling studies; IND submission on track for first half of 2027
- Ind target
- H1 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.